- Home
- OP vs CARM Comparison
OP vs CARM Comparison
Compare OP & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- CARM
- Stock Information
- Founded
- OP 2021
- CARM 2016
- Country
- OP Greece
- CARM United States
- Employees
- OP N/A
- CARM N/A
- Industry
- OP
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- CARM Health Care
- Exchange
- OP Nasdaq
- CARM Nasdaq
- Market Cap
- OP 14.3M
- CARM 12.2M
- IPO Year
- OP N/A
- CARM N/A
- Fundamental
- Price
- OP $0.07
- CARM $0.24
- Analyst Decision
- OP
- CARM Hold
- Analyst Count
- OP 0
- CARM 5
- Target Price
- OP N/A
- CARM $0.90
- AVG Volume (30 Days)
- OP 61.1M
- CARM 447.9K
- Earning Date
- OP 08-08-2025
- CARM 08-07-2025
- Dividend Yield
- OP N/A
- CARM N/A
- EPS Growth
- OP N/A
- CARM N/A
- EPS
- OP N/A
- CARM N/A
- Revenue
- OP $19,435,000.00
- CARM $10,767,000.00
- Revenue This Year
- OP N/A
- CARM N/A
- Revenue Next Year
- OP N/A
- CARM N/A
- P/E Ratio
- OP N/A
- CARM N/A
- Revenue Growth
- OP N/A
- CARM N/A
- 52 Week Low
- OP $0.06
- CARM $0.14
- 52 Week High
- OP $3.17
- CARM $1.27
- Technical
- Relative Strength Index (RSI)
- OP 32.16
- CARM 31.94
- Support Level
- OP $0.09
- CARM $0.21
- Resistance Level
- OP $0.12
- CARM $0.31
- Average True Range (ATR)
- OP 0.01
- CARM 0.03
- MACD
- OP 0.04
- CARM -0.00
- Stochastic Oscillator
- OP 3.41
- CARM 23.64
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.